Rocket Lab's Strong Q2 Highlights Growth, But Neutron and Iridium Still Gate the Thesis

What happened

Rocket Lab reported Q2 2026 revenue of $234 million, up 62% year-over-year, with record backlog of $2.36 billion and recent contract awards exceeding $1 billion, driven by Space Systems revenue of $189.5 million. The company continues to expand its integrated space platform, combining spacecraft, components, launch, and defense programs. Neutron demand remains strong ahead of its first launch, with targeted pricing of $50–$55 million per launch and management seeing potential upside to average selling prices. However, the investment case still hinges on two unresolved binary events: timely Neutron qualification and a firm launch window, and successful permanent financing for the Iridium acquisition. At the current price around $80, the stock already credits much of the growth, leaving limited margin of safety until those proof points materialize.

Implication

For existing holders, the strong Q2 print supports the stand-alone business, but the stock's valuation remains stretched relative to concrete milestones, so trimming above $95 remains prudent. New investors should resist chasing the momentum, as the next 6–12 months depend on execution risk rather than demand risk. Key monitoring points include Neutron first-stage qualification completion and a firm first-flight date by late 2026, and disclosure of permanent Iridium financing terms before the bridge matures. If Neutron slips or Iridium requires more equity than expected, the stock could retreat toward the bear-case value of $64. Conversely, successful qualification and cleaner financing could support a move toward the bull-case value of $96, but the current balance of probabilities favors patience.

Thesis delta

The latest earnings and commentary reinforce the strength of Rocket Lab's core business, but they were largely anticipated by the market and do not alter the two key binary catalysts: Neutron timing and Iridium financing. The article's optimism about Neutron pricing upside is a modest positive, but it does not de-risk the schedule or capital structure. Therefore, the thesis remains unchanged: WAIT, with a higher entry point of $65 and a trim level of $95.